epidemiological and medical burden of the covid-19
TRANSCRIPT
1
EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19 PANDEMIC IN PEDIATRIC TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL STUDY ACROSS THE ERN-TRANSPLANTCHILD MEMBERS
Fields marked with * are mandatory.
EPIDEMIOLOGICAL AND MEDICAL BURDEN OF
THE COVID-19 PANDEMIC IN PEDIATRIC TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL STUDY ACROSS THE ERN-
TRANSPLANTCHILD MEMBERS
2
D e a r c o l l e a g u e s ,
After the successful first clinical audit about COVID-19 in pediatric transplanted patients across ERN-TransplantChild members, Padova team suggested to share the data about follow up and burden of the COVID-19 pandemic in pediatric transplant recipients among TransplantChild centres. We see this survey as the continuation of the first one and an opportunity to update the experience and knowledge on the effects of the SARS-CoV-2 i n f e c t i o n i n o u r p a t i e n t s .
Please with the results of the first clinical audit.find below the file
This audit, on "Epidemiological and medical burden of the COVID-19 pandemic in is a survey about your centre approach and resources pediatric transplant recipients"
related to SARS-CoV-2 infection and clinical case description and follow up of these patients.
A first draft of the survey was elaborated by Dr. M. Cananzi, Dr. E. Benetti, Dr. F. de Corti, Dr. D. Donà and Dr. G. Perilongo from Azienda Ospedalera di Padova and after suggestions of other members, modifications were incorporated resulting in the final survey format that we are now sending to all of you.
It would be great to have your responses throughout this month of , so that we can Aprilanalyze the results and prepare the first document with them in May.
As always, here at La Paz University Hospital we will be completely willing to collaborate in everything you need.
Thanks in advance for your collaboration, and we are looking forward to hearing from you.
Find below the article we published on the previous COVID-19 survey.2020_Pediatric_transplantation_in_Europe_during_the_COVID-
19_pandemic_Early_impact_on_activity_and_healthcare.pdf
Your name
CentreVilnius University Hospital Santaros Klinikos, LithuaniaCentro Hospitalar e Universitário de Coimbra, Portugal
*
*
*
3
University Medical Center Utrecht, The NetherlandsChildren's Memorial Health Institute, PolandHospital Universitario la Paz, EspañaMedizinische Hochschule Hannover, GermanyCentro Hospitalar de Lisboa Norte, PortugalOspedale Papa Giovanni XXIII, Bergamo, ItalyCentro Hospitalar do Porto, PortugalKarolinska University Hospital, SwedenAssistance Publique Hôpitaux de Paris, Hôpital Bicêtre, FranceAssistance Publique Hôpitaux de Paris, Hôpital Necker Enfants Malades, FranceSkåne University Hospital, Lund, SwedenOspedale Pediatrico Bambino Gesù, Rome, ItalyUniversity Hospitals Saint Luc, BelgiumAzienda Ospedale Università Padova, ItalyISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyCentre for Pediatric Lung Transplantation, Medical University of Vienna, AustriaUniversity Hospital Centre Zagreb, CroatiaSemmelweis University, HungaryTartu University Hospital, EstoniaChildren’s Clinical University Hospital, Riga, LatviaCentre Hospitalier du Luxembourg, LuxembourgMater Dei Hospital, MaltaRigshospitalet University Hospital, DenmarkOdense University Hospital, DenmarkOther
Please, specify other centre name:
CENTRE-SPECIFIC QUESTIONS
Transplantation program:HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
Characteristics of your Transplant Unit:MedicalSurgicalBoth
*
*
*
4
%
patients
Type of patients:Exclusively pediatricMixed pediatric-adult
How many children with SOT/HSCT do you follow?<5051-100101-149150-199>200
WHO COVID-19 def ini t ion of conf i rmed case*
*Please answer according to the WHO COVID-19 definition of the confirmed case as either:A. a child with a positive Nucleic Acid Amplification Test (NAAT); B. a child with a positive SARS-CoV-2 antigen-rapid diagnostic test (RDT) who meets clinical criteria and is a contact of a probable or confirmed case or is linked to a COVID-19 cluster;or C. an asymptomatic child with a positive SARS-CoV-2 antigen-RDT who is a contact of a probable or c o n f i r m e d c a s e .
*See attached WHO confirmed case definition for more details, if needed. WHO-2019-nCoV-Surveillance_Case_Definition-2020.2-eng.pdf
How many of your transplanted patients have been infected by since the beginning of the SARS-CoV-2*pandemic?
Only values between 0 and 100 are allowed
Percentage of your total patients:Only values between 0 and 100 are allowed
In your centre, have you specific test to assess the specific immune response to SARS-CoV-2?IgG anti-SARS-CoV-2 titrationB lymphocyte specific responseT lymphocyte specific responseCytokines productionOtherNone
Please, specify B lymphocyte specific response technique or method:
*
*
*
*
*
*
5
months
Please, specify T lymphocyte specific response technique or method:
Please, specify cytokines production technique or method:
Please, specify other technique or methods used:
Please, fill in the specific questions for each patient with COVID-19 you have. Once you have finished, go to the Submit section to finish the survey.
1. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy
*
*
*
6
- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic
7
- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq
8
- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia
9
- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo
10
- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidneyLiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
11
months* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acid
12
Everolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:
13
NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia sppStaphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenza
14
JC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:Normal
15
Reduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
16
weeks
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
17
weeks
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:*
18
days
days
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
19
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
20
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
2. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
21
Country of residence (EU member states):AT - AustriaBE - BelgiumBG - BulgariaHR - CroatiaCY - CyprusCZ - CzechiaDK - DenmarkEE - EstoniaFI - FinlandFR - FranceDE - GermanyEL - GreeceHU - HungaryIE - IrelandIT - ItalyLV - LatviaLT - LithuaniaLU - LuxembourgMT - MaltaNL - NetherlandsPL - PolandPT - PortugalRO - RomaniaSK - Slovak RepublicSI - SloveniaES - SpainSE - Sweden
Country of residence (Non- EU member sate):AF - AfghanistanAL - AlbaniaDZ - AlgeriaAD - AndorraAO - AngolaAG - Antigua and BarbudaAR - ArgentinaAM - ArmeniaAU - AustraliaAT - AustriaAZ - AzerbaijanBS - BahamasBH - BahrainBD - BangladeshBB - BarbadosBY - Belarus
22
BE - BelgiumBZ - BelizeBJ - BeninBT - BhutanBO - BoliviaBA - Bosnia and HerzegovinaBW - BotswanaBR - BrazilBN - Brunei DarussalamBG - BulgariaBF - Burkina FasoBI - BurundiCV - Cabo VerdeKH - CambodiaCM - CameroonCA - CanadaCF - Central African RepublicTD - ChadCL - ChileCN - ChinaCO - ColombiaKM - ComorosCG - CongoCR - Costa RicaCI - Côte D'IvoireHR - CroatiaCU - CubaCY - CyprusCZ - CzechiaCD - Democratic Republic of the CongoDK - DenmarkDJ - DjiboutiDM - DominicaDO - Dominican RepublicEC - EcuadorEG - EgyptSV - El SalvadorGQ - Equatorial GuineaER - EritreaEE - EstoniaSZ - EswatiniET - EthiopiaFJ - FijiFI - FinlandFR - FranceGA - GabonGM - Gambia
23
GE - GeorgiaDE - GermanyGH - GhanaGR - GreeceGD - GrenadaGT - GuatemalaGN - GuineaGW - Guinea BissauGY - GuyanaHT - HaitiHN - HondurasHU - HungaryIS - IcelandIN - IndiaID - IndonesiaIR - IranIQ - IraqIE - IrelandIL - IsraelIT - ItalyJM - JamaicaJP - JapanJO - JordanKZ - KazakhstanKE - KenyaKI - KiribatiKW - KuwaitKG - KyrgyzstanLA - LaosLV - LatviaLB - LebanonLS - LesothoLR - LiberiaLY - LibyaLI - LiechtensteinLT - LithuaniaLU - LuxembourgMG - MadagascarMW - MalawiMY - MalaysiaMV - MaldivesML - MaliMT - MaltaMH - Marshall IslandsMR - MauritaniaMU - MauritiusMX - Mexico
24
FM - MicronesiaMC - MonacoMN - MongoliaME - MontenegroMA - MoroccoMZ - MozambiqueMM - MyanmarNA - NamibiaNR - NauruNP - NepalNL - NetherlandsNZ - New ZealandNI - NicaraguaNE - NigerNG - NigeriaKP - North KoreaMK - North MacedoniaNO - NorwayOM - OmanPK - PakistanPW - PalauPA - PanamaPG - Papua New GuineaPY - ParaguayPE - PeruPH - PhilippinesPL - PolandPT - PortugalQA - QatarMD - Republic of MoldovaRO - RomaniaRU - Russian FederationRW - RwandaKN - Saint Kitts and NevisLC - Saint LuciaVC - Saint Vincent and the GrenadinesWS - SamoaSM - San MarinoST - Sao Tome and PrincipeSA - Saudi ArabiaSN - SenegalRS - SerbiaSC - SeychellesSL - Sierra LeoneSG - SingaporeSK - SlovakiaSI - Slovenia
25
SB - Solomon IslandsSO - SomaliaZA - South AfricaKR - South KoreaSS - South SudanES - SpainLK - Sri LankaSD - SudanSR - SurinameSE - SwedenCH - SwitzerlandSY - Syrian Arab RepublicTJ - TajikistanTZ - TanzaniaTH - ThailandTL - Timor-LesteTG - TogoTO - TongaTT - Trinidad and TobagoTN - TunisiaTR - TurkeyTM - TurkmenistanTV - TuvaluUG - UgandaUA - UkraineAE - United Arab EmiratesGB - United KingdomUS - United States of AmericaUY - UruguayUZ - UzbekistanVU - VanuatuVE - VenezuelaVN - Viet NamYE - YemenZM - ZambiaZW - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
26
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
27
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
28
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
29
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
30
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
31
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
32
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
33
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
34
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
35
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
36
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
3. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
37
Country of residence (EU member states):[ID85] - Austria[ID86] - Belgium[ID87] - Bulgaria[ID88] - Croatia[ID89] - Cyprus[ID90] - Czechia[ID91] - Denmark[ID92] - Estonia[ID93] - Finland[ID94] - France[ID95] - Germany[ID96] - Greece[ID97] - Hungary[ID98] - Ireland[ID99] - Italy[ID100] - Latvia[ID101] - Lithuania[ID102] - Luxembourg[ID103] - Malta[ID104] - Netherlands[ID105] - Poland[ID106] - Portugal[ID107] - Romania[ID108] - Slovak Republic[ID109] - Slovenia[ID110] - Spain[ID111] - Sweden
Country of residence (Non- EU member sate):[ID113] - Afghanistan[ID114] - Albania[ID115] - Algeria[ID116] - Andorra[ID117] - Angola[ID118] - Antigua and Barbuda[ID119] - Argentina[ID120] - Armenia[ID121] - Australia[ID122] - Austria[ID123] - Azerbaijan[ID668] - Bahamas[ID669] - Bahrain[ID670] - Bangladesh[ID671] - Barbados[ID672] - Belarus
38
[ID673] - Belgium[ID689] - Belize[ID690] - Benin[ID691] - Bhutan[ID692] - Bolivia[ID693] - Bosnia and Herzegovina[ID694] - Botswana[ID695] - Brazil[ID696] - Brunei Darussalam[ID697] - Bulgaria[ID698] - Burkina Faso[ID699] - Burundi[ID700] - Cabo Verde[ID701] - Cambodia[ID702] - Cameroon[ID703] - Canada[ID704] - Central African Republic[ID705] - Chad[ID706] - Chile[ID707] - China[ID708] - Colombia[ID709] - Comoros[ID710] - Congo[ID711] - Costa Rica[ID716] - Côte D'Ivoire[ID712] - Croatia[ID713] - Cuba[ID714] - Cyprus[ID715] - Czechia[ID717] - Democratic Republic of the Congo[ID718] - Denmark[ID719] - Djibouti[ID720] - Dominica[ID721] - Dominican Republic[ID722] - Ecuador[ID723] - Egypt[ID724] - El Salvador[ID725] - Equatorial Guinea[ID726] - Eritrea[ID727] - Estonia[ID728] - Eswatini[ID729] - Ethiopia[ID730] - Fiji[ID731] - Finland[ID732] - France[ID733] - Gabon[ID734] - Gambia
39
[ID735] - Georgia[ID736] - Germany[ID737] - Ghana[ID738] - Greece[ID739] - Grenada[ID740] - Guatemala[ID741] - Guinea[ID742] - Guinea Bissau[ID743] - Guyana[ID744] - Haiti[ID745] - Honduras[ID746] - Hungary[ID747] - Iceland[ID748] - India[ID749] - Indonesia[ID750] - Iran[ID751] - Iraq[ID752] - Ireland[ID753] - Israel[ID754] - Italy[ID755] - Jamaica[ID756] - Japan[ID757] - Jordan[ID758] - Kazakhstan[ID759] - Kenya[ID760] - Kiribati[ID761] - Kuwait[ID762] - Kyrgyzstan[ID763] - Laos[ID764] - Latvia[ID765] - Lebanon[ID766] - Lesotho[ID767] - Liberia[ID768] - Libya[ID769] - Liechtenstein[ID770] - Lithuania[ID771] - Luxembourg[ID772] - Madagascar[ID773] - Malawi[ID774] - Malaysia[ID775] - Maldives[ID776] - Mali[ID777] - Malta[ID778] - Marshall Islands[ID779] - Mauritania[ID780] - Mauritius[ID781] - Mexico
40
[ID782] - Micronesia[ID783] - Monaco[ID784] - Mongolia[ID785] - Montenegro[ID786] - Morocco[ID787] - Mozambique[ID788] - Myanmar[ID789] - Namibia[ID790] - Nauru[ID791] - Nepal[ID792] - Netherlands[ID793] - New Zealand[ID794] - Nicaragua[ID795] - Niger[ID796] - Nigeria[ID797] - North Korea[ID798] - North Macedonia[ID799] - Norway[ID800] - Oman[ID801] - Pakistan[ID802] - Palau[ID803] - Panama[ID804] - Papua New Guinea[ID805] - Paraguay[ID806] - Peru[ID807] - Philippines[ID808] - Poland[ID809] - Portugal[ID810] - Qatar[ID811] - Republic of Moldova[ID812] - Romania[ID813] - Russian Federation[ID814] - Rwanda[ID815] - Saint Kitts and Nevis[ID816] - Saint Lucia[ID817] - Saint Vincent and the Grenadines[ID818] - Samoa[ID819] - San Marino[ID820] - Sao Tome and Principe[ID821] - Saudi Arabia[ID822] - Senegal[ID823] - Serbia[ID824] - Seychelles[ID825] - Sierra Leone[ID826] - Singapore[ID827] - Slovakia[ID828] - Slovenia
41
[ID829] - Solomon Islands[ID830] - Somalia[ID831] - South Africa[ID832] - South Korea[ID833] - South Sudan[ID834] - Spain[ID835] - Sri Lanka[ID836] - Sudan[ID837] - Suriname[ID838] - Sweden[ID839] - Switzerland[ID840] - Syrian Arab Republic[ID841] - Tajikistan[ID842] - Tanzania[ID843] - Thailand[ID844] - Timor-Leste[ID845] - Togo[ID846] - Tonga[ID847] - Trinidad and Tobago[ID848] - Tunisia[ID849] - Turkey[ID850] - Turkmenistan[ID851] - Tuvalu[ID852] - Uganda[ID853] - Ukraine[ID854] - United Arab Emirates[ID855] - United Kingdom[ID856] - United States of America[ID857] - Uruguay[ID858] - Uzbekistan[ID859] - Vanuatu[ID860] - Venezuela[ID861] - Viet Nam[ID862] - Yemen[ID863] - Zambia[ID864] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
42
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
43
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
44
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
45
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
46
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
47
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
48
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
49
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
50
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
51
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
52
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
4. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
53
Country of residence (EU member states):[ID1122] - Austria[ID1123] - Belgium[ID1139] - Bulgaria[ID1140] - Croatia[ID1141] - Cyprus[ID1142] - Czechia[ID1143] - Denmark[ID1144] - Estonia[ID1145] - Finland[ID1146] - France[ID1147] - Germany[ID1148] - Greece[ID1149] - Hungary[ID1150] - Ireland[ID1151] - Italy[ID1152] - Latvia[ID1153] - Lithuania[ID1154] - Luxembourg[ID1155] - Malta[ID1156] - Netherlands[ID1157] - Poland[ID1158] - Portugal[ID1159] - Romania[ID1160] - Slovak Republic[ID1161] - Slovenia[ID1162] - Spain[ID1163] - Sweden
Country of residence (Non- EU member sate):[ID1165] - Afghanistan[ID1166] - Albania[ID1167] - Algeria[ID1168] - Andorra[ID1169] - Angola[ID1170] - Antigua and Barbuda[ID1171] - Argentina[ID1172] - Armenia[ID1173] - Australia[ID1174] - Austria[ID1175] - Azerbaijan[ID1176] - Bahamas[ID1177] - Bahrain[ID1178] - Bangladesh[ID1179] - Barbados[ID1180] - Belarus
54
[ID1181] - Belgium[ID1182] - Belize[ID1183] - Benin[ID1184] - Bhutan[ID1185] - Bolivia[ID1186] - Bosnia and Herzegovina[ID1187] - Botswana[ID1188] - Brazil[ID1189] - Brunei Darussalam[ID1190] - Bulgaria[ID1191] - Burkina Faso[ID1192] - Burundi[ID1193] - Cabo Verde[ID1194] - Cambodia[ID1195] - Cameroon[ID1196] - Canada[ID1197] - Central African Republic[ID1198] - Chad[ID1199] - Chile[ID1200] - China[ID1201] - Colombia[ID1202] - Comoros[ID1203] - Congo[ID1204] - Costa Rica[ID1209] - Côte D'Ivoire[ID1205] - Croatia[ID1206] - Cuba[ID1207] - Cyprus[ID1208] - Czechia[ID1210] - Democratic Republic of the Congo[ID1211] - Denmark[ID1212] - Djibouti[ID1213] - Dominica[ID1214] - Dominican Republic[ID1215] - Ecuador[ID1216] - Egypt[ID1217] - El Salvador[ID1218] - Equatorial Guinea[ID1219] - Eritrea[ID1220] - Estonia[ID1221] - Eswatini[ID1222] - Ethiopia[ID1223] - Fiji[ID1224] - Finland[ID1225] - France[ID1226] - Gabon[ID1227] - Gambia
55
[ID1228] - Georgia[ID1229] - Germany[ID1230] - Ghana[ID1231] - Greece[ID1232] - Grenada[ID1233] - Guatemala[ID1234] - Guinea[ID1235] - Guinea Bissau[ID1236] - Guyana[ID1237] - Haiti[ID1238] - Honduras[ID1239] - Hungary[ID1240] - Iceland[ID1241] - India[ID1242] - Indonesia[ID1243] - Iran[ID1244] - Iraq[ID1245] - Ireland[ID1246] - Israel[ID1247] - Italy[ID1248] - Jamaica[ID1249] - Japan[ID1250] - Jordan[ID1251] - Kazakhstan[ID1252] - Kenya[ID1253] - Kiribati[ID1254] - Kuwait[ID1255] - Kyrgyzstan[ID1256] - Laos[ID1257] - Latvia[ID1258] - Lebanon[ID1259] - Lesotho[ID1260] - Liberia[ID1261] - Libya[ID1262] - Liechtenstein[ID1263] - Lithuania[ID1264] - Luxembourg[ID1265] - Madagascar[ID1266] - Malawi[ID1267] - Malaysia[ID1268] - Maldives[ID1269] - Mali[ID1270] - Malta[ID1271] - Marshall Islands[ID1272] - Mauritania[ID1273] - Mauritius[ID1274] - Mexico
56
[ID1275] - Micronesia[ID1276] - Monaco[ID1277] - Mongolia[ID1278] - Montenegro[ID1279] - Morocco[ID1280] - Mozambique[ID1281] - Myanmar[ID1282] - Namibia[ID1283] - Nauru[ID1284] - Nepal[ID1285] - Netherlands[ID1286] - New Zealand[ID1287] - Nicaragua[ID1288] - Niger[ID1289] - Nigeria[ID1290] - North Korea[ID1291] - North Macedonia[ID1292] - Norway[ID1293] - Oman[ID1294] - Pakistan[ID1295] - Palau[ID1296] - Panama[ID1297] - Papua New Guinea[ID1298] - Paraguay[ID1299] - Peru[ID1300] - Philippines[ID1301] - Poland[ID1302] - Portugal[ID1303] - Qatar[ID1304] - Republic of Moldova[ID1305] - Romania[ID1306] - Russian Federation[ID1307] - Rwanda[ID1308] - Saint Kitts and Nevis[ID1309] - Saint Lucia[ID1310] - Saint Vincent and the Grenadines[ID1311] - Samoa[ID1312] - San Marino[ID1313] - Sao Tome and Principe[ID1314] - Saudi Arabia[ID1315] - Senegal[ID1316] - Serbia[ID1317] - Seychelles[ID1318] - Sierra Leone[ID1319] - Singapore[ID1320] - Slovakia[ID1321] - Slovenia
57
[ID1322] - Solomon Islands[ID1323] - Somalia[ID1324] - South Africa[ID1325] - South Korea[ID1326] - South Sudan[ID1327] - Spain[ID1328] - Sri Lanka[ID1329] - Sudan[ID1330] - Suriname[ID1331] - Sweden[ID1332] - Switzerland[ID1333] - Syrian Arab Republic[ID1334] - Tajikistan[ID1335] - Tanzania[ID1336] - Thailand[ID1337] - Timor-Leste[ID1338] - Togo[ID1339] - Tonga[ID1340] - Trinidad and Tobago[ID1341] - Tunisia[ID1342] - Turkey[ID1343] - Turkmenistan[ID1344] - Tuvalu[ID1345] - Uganda[ID1346] - Ukraine[ID1347] - United Arab Emirates[ID1348] - United Kingdom[ID1349] - United States of America[ID1350] - Uruguay[ID1351] - Uzbekistan[ID1352] - Vanuatu[ID1353] - Venezuela[ID1354] - Viet Nam[ID1355] - Yemen[ID1356] - Zambia[ID1357] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
58
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
59
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
60
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
61
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
62
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
63
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
64
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
65
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
66
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
67
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
68
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
5. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
69
Country of residence (EU member states):[ID1636] - Austria[ID1637] - Belgium[ID1638] - Bulgaria[ID1639] - Croatia[ID1640] - Cyprus[ID1641] - Czechia[ID1642] - Denmark[ID1643] - Estonia[ID1644] - Finland[ID1645] - France[ID1646] - Germany[ID1647] - Greece[ID1648] - Hungary[ID1649] - Ireland[ID1650] - Italy[ID1651] - Latvia[ID1652] - Lithuania[ID1653] - Luxembourg[ID1654] - Malta[ID1655] - Netherlands[ID1656] - Poland[ID1657] - Portugal[ID1658] - Romania[ID1659] - Slovak Republic[ID1660] - Slovenia[ID1661] - Spain[ID1662] - Sweden
Country of residence (Non- EU member sate):[ID1664] - Afghanistan[ID1665] - Albania[ID1666] - Algeria[ID1667] - Andorra[ID1668] - Angola[ID1669] - Antigua and Barbuda[ID1670] - Argentina[ID1671] - Armenia[ID1672] - Australia[ID1673] - Austria[ID1674] - Azerbaijan[ID1675] - Bahamas[ID1676] - Bahrain[ID1677] - Bangladesh[ID1678] - Barbados[ID1679] - Belarus
70
[ID1680] - Belgium[ID1681] - Belize[ID1682] - Benin[ID1683] - Bhutan[ID1684] - Bolivia[ID1685] - Bosnia and Herzegovina[ID1686] - Botswana[ID1687] - Brazil[ID1688] - Brunei Darussalam[ID1689] - Bulgaria[ID1690] - Burkina Faso[ID1691] - Burundi[ID1692] - Cabo Verde[ID1693] - Cambodia[ID1694] - Cameroon[ID1695] - Canada[ID1696] - Central African Republic[ID1697] - Chad[ID1698] - Chile[ID1699] - China[ID1700] - Colombia[ID1701] - Comoros[ID1702] - Congo[ID1703] - Costa Rica[ID1708] - Côte D'Ivoire[ID1704] - Croatia[ID1705] - Cuba[ID1706] - Cyprus[ID1707] - Czechia[ID1709] - Democratic Republic of the Congo[ID1710] - Denmark[ID1711] - Djibouti[ID1712] - Dominica[ID1713] - Dominican Republic[ID1714] - Ecuador[ID1715] - Egypt[ID1716] - El Salvador[ID1717] - Equatorial Guinea[ID1718] - Eritrea[ID1719] - Estonia[ID1720] - Eswatini[ID1721] - Ethiopia[ID1722] - Fiji[ID1723] - Finland[ID1724] - France[ID1725] - Gabon[ID1726] - Gambia
71
[ID1727] - Georgia[ID1728] - Germany[ID1729] - Ghana[ID1730] - Greece[ID1731] - Grenada[ID1732] - Guatemala[ID1733] - Guinea[ID1734] - Guinea Bissau[ID1735] - Guyana[ID1736] - Haiti[ID1737] - Honduras[ID1738] - Hungary[ID1739] - Iceland[ID1740] - India[ID1741] - Indonesia[ID1742] - Iran[ID1743] - Iraq[ID1744] - Ireland[ID1745] - Israel[ID1746] - Italy[ID1747] - Jamaica[ID1748] - Japan[ID1749] - Jordan[ID1750] - Kazakhstan[ID1751] - Kenya[ID1752] - Kiribati[ID1753] - Kuwait[ID1754] - Kyrgyzstan[ID1755] - Laos[ID1756] - Latvia[ID1757] - Lebanon[ID1758] - Lesotho[ID1759] - Liberia[ID1760] - Libya[ID1761] - Liechtenstein[ID1762] - Lithuania[ID1763] - Luxembourg[ID1764] - Madagascar[ID1765] - Malawi[ID1766] - Malaysia[ID1767] - Maldives[ID1768] - Mali[ID1769] - Malta[ID1770] - Marshall Islands[ID1771] - Mauritania[ID1772] - Mauritius[ID1773] - Mexico
72
[ID1774] - Micronesia[ID1775] - Monaco[ID1776] - Mongolia[ID1777] - Montenegro[ID1778] - Morocco[ID1779] - Mozambique[ID1780] - Myanmar[ID1781] - Namibia[ID1782] - Nauru[ID1783] - Nepal[ID1784] - Netherlands[ID1785] - New Zealand[ID1786] - Nicaragua[ID1787] - Niger[ID1788] - Nigeria[ID1789] - North Korea[ID1793] - North Macedonia[ID1794] - Norway[ID1795] - Oman[ID1796] - Pakistan[ID1797] - Palau[ID1798] - Panama[ID1799] - Papua New Guinea[ID1800] - Paraguay[ID1801] - Peru[ID1802] - Philippines[ID1803] - Poland[ID1804] - Portugal[ID1805] - Qatar[ID1806] - Republic of Moldova[ID1807] - Romania[ID1808] - Russian Federation[ID1809] - Rwanda[ID1810] - Saint Kitts and Nevis[ID1811] - Saint Lucia[ID1812] - Saint Vincent and the Grenadines[ID1813] - Samoa[ID1814] - San Marino[ID1815] - Sao Tome and Principe[ID1816] - Saudi Arabia[ID1817] - Senegal[ID1818] - Serbia[ID1819] - Seychelles[ID1820] - Sierra Leone[ID1821] - Singapore[ID1822] - Slovakia[ID1823] - Slovenia
73
[ID1824] - Solomon Islands[ID1825] - Somalia[ID1826] - South Africa[ID1827] - South Korea[ID1828] - South Sudan[ID1829] - Spain[ID1830] - Sri Lanka[ID1831] - Sudan[ID1832] - Suriname[ID1833] - Sweden[ID1834] - Switzerland[ID1835] - Syrian Arab Republic[ID1836] - Tajikistan[ID1837] - Tanzania[ID1838] - Thailand[ID1839] - Timor-Leste[ID1840] - Togo[ID1841] - Tonga[ID1842] - Trinidad and Tobago[ID1843] - Tunisia[ID1844] - Turkey[ID1845] - Turkmenistan[ID1846] - Tuvalu[ID1847] - Uganda[ID1848] - Ukraine[ID1849] - United Arab Emirates[ID1850] - United Kingdom[ID1851] - United States of America[ID1852] - Uruguay[ID1853] - Uzbekistan[ID1854] - Vanuatu[ID1855] - Venezuela[ID1856] - Viet Nam[ID1857] - Yemen[ID1858] - Zambia[ID1859] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
74
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
75
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
76
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
77
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
78
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
79
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
80
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
81
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
82
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
83
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
84
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
6. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
85
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
86
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
87
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
88
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
89
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
90
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
91
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
92
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
93
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
94
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
95
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
96
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
97
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
98
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
99
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
100
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
7. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
101
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
102
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
103
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
104
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
105
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
106
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
107
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
108
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
109
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
110
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
111
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
112
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
113
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
114
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
115
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
116
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
8. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
117
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
118
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
119
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
120
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
121
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
122
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
123
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
124
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
125
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
126
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
127
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
128
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
129
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
130
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
131
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
132
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
9. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
133
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
134
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
135
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
136
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
137
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
138
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
139
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
140
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
141
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
142
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
143
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
144
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
145
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
146
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
147
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
148
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
10. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
149
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
150
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
151
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
152
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
153
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
154
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
155
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
156
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
157
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
158
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
159
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
160
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
161
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
162
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
163
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
164
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
11. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
165
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
166
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
167
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
168
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
169
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
170
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
171
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
172
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
173
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
174
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
175
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
176
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
177
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
178
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
179
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
180
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
12. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
181
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
182
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
183
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
184
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
185
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
186
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
187
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
188
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
189
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
190
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
191
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
192
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
193
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
194
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
195
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
196
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
13. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
197
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
198
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
199
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
200
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
201
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
202
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
203
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
204
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
205
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
206
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
207
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
208
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
209
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
210
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
211
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
212
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
14. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
213
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
214
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
215
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
216
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
217
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
218
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
219
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
220
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
221
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
222
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
223
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
224
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
225
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
226
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
227
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
228
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
15. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
229
Country of residence (EU member states):[ID81] - Austria[ID388] - Belgium[ID389] - Bulgaria[ID390] - Croatia[ID391] - Cyprus[ID392] - Czechia[ID393] - Denmark[ID394] - Estonia[ID395] - Finland[ID396] - France[ID397] - Germany[ID398] - Greece[ID399] - Hungary[ID400] - Ireland[ID401] - Italy[ID402] - Latvia[ID403] - Lithuania[ID404] - Luxembourg[ID405] - Malta[ID406] - Netherlands[ID407] - Poland[ID408] - Portugal[ID409] - Romania[ID410] - Slovak Republic[ID411] - Slovenia[ID412] - Spain[ID413] - Sweden
Country of residence (Non- EU member sate):[ID415] - Afghanistan[ID416] - Albania[ID417] - Algeria[ID418] - Andorra[ID419] - Angola[ID420] - Antigua and Barbuda[ID421] - Argentina[ID422] - Armenia[ID423] - Australia[ID424] - Austria[ID425] - Azerbaijan[ID426] - Bahamas[ID427] - Bahrain[ID428] - Bangladesh[ID429] - Barbados[ID430] - Belarus
230
[ID431] - Belgium[ID432] - Belize[ID433] - Benin[ID434] - Bhutan[ID435] - Bolivia[ID436] - Bosnia and Herzegovina[ID437] - Botswana[ID438] - Brazil[ID439] - Brunei Darussalam[ID440] - Bulgaria[ID441] - Burkina Faso[ID442] - Burundi[ID443] - Cabo Verde[ID444] - Cambodia[ID445] - Cameroon[ID446] - Canada[ID447] - Central African Republic[ID448] - Chad[ID449] - Chile[ID450] - China[ID451] - Colombia[ID452] - Comoros[ID453] - Congo[ID454] - Costa Rica[ID459] - Côte D'Ivoire[ID455] - Croatia[ID456] - Cuba[ID457] - Cyprus[ID458] - Czechia[ID460] - Democratic Republic of the Congo[ID461] - Denmark[ID462] - Djibouti[ID463] - Dominica[ID464] - Dominican Republic[ID465] - Ecuador[ID466] - Egypt[ID467] - El Salvador[ID468] - Equatorial Guinea[ID469] - Eritrea[ID470] - Estonia[ID471] - Eswatini[ID472] - Ethiopia[ID473] - Fiji[ID474] - Finland[ID475] - France[ID476] - Gabon[ID477] - Gambia
231
[ID478] - Georgia[ID479] - Germany[ID480] - Ghana[ID481] - Greece[ID482] - Grenada[ID483] - Guatemala[ID484] - Guinea[ID485] - Guinea Bissau[ID486] - Guyana[ID487] - Haiti[ID488] - Honduras[ID489] - Hungary[ID490] - Iceland[ID491] - India[ID492] - Indonesia[ID493] - Iran[ID494] - Iraq[ID495] - Ireland[ID496] - Israel[ID497] - Italy[ID498] - Jamaica[ID499] - Japan[ID500] - Jordan[ID501] - Kazakhstan[ID502] - Kenya[ID503] - Kiribati[ID504] - Kuwait[ID505] - Kyrgyzstan[ID506] - Laos[ID507] - Latvia[ID508] - Lebanon[ID509] - Lesotho[ID510] - Liberia[ID511] - Libya[ID512] - Liechtenstein[ID513] - Lithuania[ID514] - Luxembourg[ID515] - Madagascar[ID516] - Malawi[ID517] - Malaysia[ID518] - Maldives[ID519] - Mali[ID520] - Malta[ID521] - Marshall Islands[ID522] - Mauritania[ID523] - Mauritius[ID524] - Mexico
232
[ID525] - Micronesia[ID526] - Monaco[ID527] - Mongolia[ID528] - Montenegro[ID529] - Morocco[ID530] - Mozambique[ID531] - Myanmar[ID532] - Namibia[ID533] - Nauru[ID534] - Nepal[ID535] - Netherlands[ID536] - New Zealand[ID537] - Nicaragua[ID538] - Niger[ID539] - Nigeria[ID540] - North Korea[ID541] - North Macedonia[ID542] - Norway[ID543] - Oman[ID544] - Pakistan[ID545] - Palau[ID546] - Panama[ID547] - Papua New Guinea[ID548] - Paraguay[ID549] - Peru[ID550] - Philippines[ID551] - Poland[ID552] - Portugal[ID553] - Qatar[ID554] - Republic of Moldova[ID555] - Romania[ID556] - Russian Federation[ID557] - Rwanda[ID558] - Saint Kitts and Nevis[ID559] - Saint Lucia[ID560] - Saint Vincent and the Grenadines[ID561] - Samoa[ID562] - San Marino[ID563] - Sao Tome and Principe[ID564] - Saudi Arabia[ID565] - Senegal[ID566] - Serbia[ID567] - Seychelles[ID568] - Sierra Leone[ID569] - Singapore[ID570] - Slovakia[ID571] - Slovenia
233
[ID572] - Solomon Islands[ID573] - Somalia[ID574] - South Africa[ID575] - South Korea[ID576] - South Sudan[ID577] - Spain[ID578] - Sri Lanka[ID579] - Sudan[ID580] - Suriname[ID581] - Sweden[ID582] - Switzerland[ID583] - Syrian Arab Republic[ID584] - Tajikistan[ID585] - Tanzania[ID586] - Thailand[ID587] - Timor-Leste[ID588] - Togo[ID589] - Tonga[ID590] - Trinidad and Tobago[ID591] - Tunisia[ID592] - Turkey[ID593] - Turkmenistan[ID594] - Tuvalu[ID595] - Uganda[ID596] - Ukraine[ID597] - United Arab Emirates[ID598] - United Kingdom[ID599] - United States of America[ID600] - Uruguay[ID601] - Uzbekistan[ID602] - Vanuatu[ID603] - Venezuela[ID604] - Viet Nam[ID605] - Yemen[ID606] - Zambia[ID607] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
234
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
235
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
236
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
237
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
238
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
239
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
240
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
241
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
242
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
243
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
244
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
SUBMIT
If you have more than fifteen cases to report, please submit a new survey.
245